Tandem Autologous Transplantation Can Overcome the Poor Prognosis of Double-Hit Multiple Myeloma Patients With 1q21 Gain/Amp and t(4;14)

被引：0
|
作者：
Huang, Beihui [1 ]
Li, Juan [1 ]
Wang, Xiuju [2 ]
Huang, Hongming [3 ]
Xu, Xiaojun [4 ]
Wu, Bingyi [5 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[3] Nantong Univ, Affiliated Hosp, Nantong, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 7, Guangzhou, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-339
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [41] Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation
    Sasaki, Koji
    Saliba, Rima
    Lu, Gary
    Shah, Nina
    Bashir, Qaiser
    Patel, Krina
    Bock, Fabian
    Parmar, Simrit
    Hosing, Chitra
    Popat, Uday R.
    Delgado, Ruby
    Rondon, Gabriela
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S202 - S203
  • [42] The prognostic value of 1q21 gain does not rely on the copy numbers, clone size and concurrence with t(4;14)
    Du, Chenxing
    An, Gang
    Xu, Yan
    Mao, Xuehan
    Liu Jiahui
    Fan Huishou
    Wang, Qi
    Sui Weiwei
    Deng, Shuhui
    Fu, Mingwei
    Zengjun, Lizengjun
    Yi, Shuhua
    Zou, Dehui
    Qiu, Lugui
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E62 - E63
  • [43] Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma
    Xiao Xiao
    Fang, Xinchen
    Wen Yao
    Zhu Huaiping
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (01) : 90 - 93
  • [44] Bortezomib-Based Induction Therapy Followed by Autologous Stem Cell Transplantation and Maintenance Therapy with Bortezomib Improves Outcome In Myeloma Patients with Gain 1q21 and t(4;14) - a Subgroup Analysis of the HOVON-65/GMMG-HD4 Trial
    Goldschmidt, Hartmut
    Neben, Kai
    Bertsch, Uta
    Hielscher, Thomas
    van der Holt, Bronno
    Hose, Dirk
    el Jarari, Laila
    Salwender, Hans
    Blau, Igor Wolfgang
    Pfreundschuh, Michael
    Duehrsen, Ulrich
    Weisel, Katja
    Martin, Hans
    Lindemann, Walter
    Teschendorf, Christian
    Haenel, Mathias
    Scheid, Christof
    van de Velde, Helgi
    Derigs, Hans Guenter
    Hoffmann, Martin
    Peter, Norma
    Kaufmann, Martin
    Schmidt-Wolf, Ingo
    Jauch, Anna
    Lokhorst, Henk M.
    Sonneveld, Pieter
    BLOOD, 2010, 116 (21) : 138 - 139
  • [45] Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma
    Xiao Xiao
    Xinchen Fang
    Wen Yao
    Zhu Huaiping
    memo - Magazine of European Medical Oncology, 2022, 15 : 90 - 93
  • [46] Prognostic Value and Efficacy Evaluation of Novel Drugs for Multiple Myeloma Patients with 1q21 Amplification (Amp1q21) Only: A Systematic Review of Randomized Controlled Trials
    Chen, Liang
    Li, Zhendong
    Li, Shanshan
    Fu, Weijun
    Li, Rong
    JOURNAL OF CANCER, 2020, 11 (09): : 2639 - 2644
  • [47] T(4;14) Is Not a Poor Prognostic Factor for Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation in New Drug Era
    Geng, Chuanying
    Yang, Guangzhong
    Gao, Wen
    Wang, Huijuan
    Li, Yanchen
    Wu, Yin
    Zhou, Huixing
    Zhang, Zhiyao
    Jian, Yuan
    Chen, Wenming
    BLOOD, 2020, 136
  • [48] Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma
    Tao, Yi
    Jin, Shiwei
    Yang, Dan
    Pan, Mengmeng
    Ouyang, Wanyan
    Liu, Yuanfang
    Wang, Yan
    Zhang, Weiping
    Mi, Jianqing
    BMC CANCER, 2024, 24 (01)
  • [49] Newly diagnosed multiple myeloma patients with 1q21 amplification treated by autologous stem cell transplantation have shorter progression-free survival interval.
    Nemec, Pavel
    Greslikova, Henrieta
    Kuglik, Petr
    Filkova, Hana
    Zaoralova, Romana
    Vranova, Vladimira
    Smejkalova, Jana
    Vidlakova, Petra
    Oltova, Alexandra
    Hajek, Roman
    BLOOD, 2007, 110 (11) : 263B - 263B
  • [50] Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
    Liu, Xiao
    Jia, Shuangshuang
    Chu, Yuping
    Tian, Biao
    Gao, Yaya
    Zhang, Chunyan
    Zheng, Yanhua
    Jia, Weijing
    Liu, Xiangxiang
    Yuan, Ruifeng
    Zhang, Na
    Feng, Juan
    Dong, Hongjuan
    Xin, Xiaoli
    Cao, Zhengcong
    Tang, Hailong
    Chang, Ziwei
    Gao, Guangxun
    FRONTIERS IN ONCOLOGY, 2022, 12
12345